دورية أكاديمية
أعرض في EDS

Epigenetic regulation in human melanoma: past and future.

التفاصيل البيبلوغرافية
العنوان: Epigenetic regulation in human melanoma: past and future.
المؤلفون: Sarkar D; a Auckland Cancer Society Research Center ; University of Auckland ; Auckland , New Zealand., Leung EY, Baguley BC, Finlay GJ, Askarian-Amiri ME
المصدر: Epigenetics [Epigenetics] 2015; Vol. 10 (2), pp. 103-21.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Review
اللغة: English
بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101265293 Publication Model: Print Cited Medium: Internet ISSN: 1559-2308 (Electronic) Linking ISSN: 15592294 NLM ISO Abbreviation: Epigenetics Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Georgetown, Tex. : Landes Bioscience, c2006-
مواضيع طبية MeSH: Epigenesis, Genetic* , Gene Expression Regulation, Neoplastic*, Melanoma/*genetics, Carcinogenesis/genetics ; Chromatin Assembly and Disassembly ; DNA Methylation ; Histones/metabolism ; Humans ; Melanoma/pathology ; Protein Processing, Post-Translational ; Proto-Oncogene Mas ; RNA, Long Noncoding/metabolism ; Signal Transduction
مستخلص: The development and progression of melanoma have been attributed to independent or combined genetic and epigenetic events. There has been remarkable progress in understanding melanoma pathogenesis in terms of genetic alterations. However, recent studies have revealed a complex involvement of epigenetic mechanisms in the regulation of gene expression, including methylation, chromatin modification and remodeling, and the diverse activities of non-coding RNAs. The roles of gene methylation and miRNAs have been relatively well studied in melanoma, but other studies have shown that changes in chromatin status and in the differential expression of long non-coding RNAs can lead to altered regulation of key genes. Taken together, they affect the functioning of signaling pathways that influence each other, intersect, and form networks in which local perturbations disturb the activity of the whole system. Here, we focus on how epigenetic events intertwine with these pathways and contribute to the molecular pathogenesis of melanoma.
References: Genes Dev. 2012 Jun 1;26(11):1131-55. (PMID: 22661227)
Biochim Biophys Acta. 2012 Aug;1826(1):89-102. (PMID: 22503822)
Melanoma Res. 2013 Jun;23(3):218-20. (PMID: 23458759)
Am J Pathol. 2002 Jul;161(1):229-37. (PMID: 12107107)
Nat Cell Biol. 2013 Oct;15(10):1153-63. (PMID: 23974039)
Pigment Cell Melanoma Res. 2008 Oct;21(5):545-58. (PMID: 18627528)
Oncotarget. 2014 Apr 30;5(8):2276-92. (PMID: 24810364)
Oncogene. 2012 Mar 22;31(12):1558-70. (PMID: 21860416)
Cell Stem Cell. 2011 Mar 4;8(3):294-308. (PMID: 21362569)
Curr Cancer Drug Targets. 2013 Oct;13(8):843-66. (PMID: 23675881)
Epigenetics. 2010 Aug 16;5(6):469-75. (PMID: 20543574)
Oncogene. 2006 May 11;25(20):2873-84. (PMID: 16407841)
Bioessays. 2013 Dec;35(12):1093-100. (PMID: 24115003)
Melanoma Res. 2014 Aug;24(4):335-41. (PMID: 24892958)
Biochem Biophys Res Commun. 2009 Feb 13;379(3):790-4. (PMID: 19126397)
RNA. 2013 Apr;19(4):429-42. (PMID: 23431328)
Cell Signal. 2013 May;25(5):1086-95. (PMID: 23416462)
Cell Cycle. 2012 Jan 15;11(2):286-95. (PMID: 22189819)
Nat Rev Cancer. 2006 Nov;6(11):846-56. (PMID: 17060944)
Oncogene. 2004 May 13;23(22):4014-22. (PMID: 15064737)
Int J Oncol. 2013 Apr;42(4):1443-51. (PMID: 23404256)
Am J Pathol. 2012 Nov;181(5):1823-35. (PMID: 22982443)
Cancer Res. 2011 Jun 1;71(11):3852-62. (PMID: 21558391)
Mol Cancer Res. 2011 Apr;9(4):418-29. (PMID: 21383005)
Int J Oncol. 2012 Jul;41(1):276-84. (PMID: 22576688)
Dermatology. 2006;213(3):192-9. (PMID: 17033167)
J Invest Dermatol. 2004 Mar;122(3):805-11. (PMID: 15086568)
Mol Cell. 2014 Sep 18;55(6):904-15. (PMID: 25219500)
Nature. 2014 Oct 9;514(7521):247-51. (PMID: 25119042)
Melanoma Res. 2004 Jun;14(3):173-81. (PMID: 15179185)
Biomed Res Int. 2013;2013:251098. (PMID: 23862139)
J Invest Dermatol. 2012 Mar;132(3 Pt 2):854-63. (PMID: 22217739)
Oncogene. 2011 Apr 21;30(16):1956-62. (PMID: 21151178)
Biochem Biophys Res Commun. 2013 Mar 22;432(4):612-7. (PMID: 23438432)
Cancer Cell. 2009 Dec 8;16(6):498-509. (PMID: 19962668)
J Natl Cancer Inst. 2014 Feb;106(2):djt435. (PMID: 24511108)
Cancer Res. 2001 Jul 1;61(13):5303-6. (PMID: 11431374)
PLoS One. 2011;6(10):e26121. (PMID: 22028813)
J Biol Chem. 2012 Apr 6;287(15):11769-77. (PMID: 22354972)
Melanoma Res. 2010 Oct;20(5):372-80. (PMID: 20700063)
Cancer Cell. 2011 Jul 12;20(1):104-18. (PMID: 21741600)
Atherosclerosis. 2012 Feb;220(2):449-55. (PMID: 22178423)
Nature. 2014 Jul 24;511(7510):478-82. (PMID: 24919155)
PLoS One. 2011;6(4):e18936. (PMID: 21541354)
J Clin Oncol. 2006 Jan 10;24(2):268-73. (PMID: 16330673)
BMC Cancer. 2013;13:325. (PMID: 23816148)
Trends Mol Med. 2007 Sep;13(9):373-80. (PMID: 17822959)
PLoS Genet. 2010;6(12):e1001233. (PMID: 21151960)
Genome Res. 2009 Aug;19(8):1462-70. (PMID: 19491193)
Oncol Rep. 2010 Sep;24(3):701-7. (PMID: 20664976)
Cell Mol Life Sci. 2013 Feb;70(3):545-58. (PMID: 23001011)
J Biol Chem. 2008 May 30;283(22):14910-4. (PMID: 18411277)
Cancer Lett. 2013 Dec 1;341(2):240-7. (PMID: 23962556)
Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15840-5. (PMID: 21896753)
J Biol Chem. 2006 Jul 21;281(29):20233-41. (PMID: 16648630)
Nucleic Acids Res. 2010 Sep;38(16):5366-83. (PMID: 20423907)
Pigment Cell Melanoma Res. 2013 May;26(3):377-91. (PMID: 23480510)
Cancer Res. 2006 Dec 1;66(23):11187-93. (PMID: 17145863)
Am J Pathol. 2010 May;176(5):2520-9. (PMID: 20304954)
Nat Genet. 2009 May;41(5):544-52. (PMID: 19282848)
Science. 2008 Dec 12;322(5908):1695-9. (PMID: 19008416)
Clin Cancer Res. 2009 Mar 1;15(5):1801-7. (PMID: 19223509)
EMBO J. 2011 May 18;30(10):1990-2007. (PMID: 21468029)
J Biochem. 2005 Mar;137(3):431-40. (PMID: 15809347)
Cancer Biother Radiopharm. 2014 Mar;29(2):53-7. (PMID: 24380630)
Genome Res. 2012 Jun;22(6):1006-14. (PMID: 22581800)
PLoS One. 2014;9(6):e100893. (PMID: 24967732)
Oncogene. 2004 Jul 1;23(30):5215-26. (PMID: 15133491)
Exp Ther Med. 2012 May;3(5):793-796. (PMID: 22969970)
PLoS One. 2011;6(4):e18674. (PMID: 21494614)
J Clin Oncol. 2005 Dec 20;23(36):9351-8. (PMID: 16361635)
J Invest Dermatol. 2013 May;133(5):1286-93. (PMID: 23190898)
Nat Rev Mol Cell Biol. 2006 Sep;7(9):667-77. (PMID: 16921403)
Genes Dev. 2012 Feb 15;26(4):338-43. (PMID: 22302877)
Int J Mol Sci. 2013;14(7):14321-32. (PMID: 23846726)
Stem Cells. 2014 Nov;32(11):2858-68. (PMID: 25070049)
Lancet Oncol. 2007 Jan;8(1):46-54. (PMID: 17196510)
Biochemistry. 2013 Dec 31;52(52):9519-27. (PMID: 24320048)
Nat Cell Biol. 2008 May;10(5):593-601. (PMID: 18376396)
J Invest Dermatol. 2006 Sep;126(9):2111-8. (PMID: 16691193)
BMC Immunol. 2012;13:48. (PMID: 22908963)
Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1814-9. (PMID: 19188590)
J Transl Med. 2013;11:218. (PMID: 24047116)
Cell. 2002 Jun 14;109(6):707-18. (PMID: 12086670)
Melanoma Res. 2010 Aug;20(4):253-65. (PMID: 20418788)
Int J Mol Sci. 2013 Feb 26;14(3):4655-69. (PMID: 23443164)
J Am Acad Dermatol. 2014 Jun;70(6):1036-44. (PMID: 24698703)
Actas Dermosifiliogr. 2012 Sep;103(7):579-90. (PMID: 22261672)
Oncotarget. 2012 Sep;3(9):1011-25. (PMID: 22948084)
Oncogene. 2006 Nov 9;25(53):7059-69. (PMID: 16715130)
Int J Oncol. 2007 Mar;30(3):689-94. (PMID: 17273770)
Nat Commun. 2013;4:1508. (PMID: 23443536)
J Genet Genomics. 2013 Apr 20;40(4):179-88. (PMID: 23618401)
Oncogene. 2008 Nov 6;27(52):6698-706. (PMID: 18679415)
J Transl Med. 2010;8:56. (PMID: 20540720)
Cell Death Dis. 2014;5:e1298. (PMID: 24967960)
Ann Surg Oncol. 2011 May;18(5):1243-50. (PMID: 21327457)
Cancer Res. 2006 Jul 1;66(13):6546-52. (PMID: 16818626)
Exp Dermatol. 2010 Sep;19(9):854-6. (PMID: 20698882)
Toxicol In Vitro. 2015 Feb;29(1):242-50. (PMID: 25448810)
PLoS One. 2010;5(7):e11574. (PMID: 20644734)
Cell. 2011 Oct 14;147(2):382-95. (PMID: 22000016)
Oncol Lett. 2014 Nov;8(5):2201-2202. (PMID: 25295108)
Hum Mol Genet. 2013 Nov 15;22(22):4516-27. (PMID: 23813974)
Cancer Sci. 2004 Dec;95(12):962-8. (PMID: 15596045)
Angiogenesis. 2014 Jan;17(1):163-77. (PMID: 24221409)
J Immunother. 2002 Jan-Feb;25(1):16-26. (PMID: 11924907)
Nature. 2013 Mar 21;495(7441):384-8. (PMID: 23446346)
Cancer Res. 2007 Apr 15;67(8):3963-9. (PMID: 17440112)
J Invest Dermatol. 2013 Jul;133(7):1827-33. (PMID: 23364479)
J Pathol. 2012 Jan;226(1):61-72. (PMID: 22131135)
Oncogene. 2003 May 19;22(20):3092-8. (PMID: 12789286)
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13421-6. (PMID: 18755897)
Lab Invest. 2014 Aug;94(8):822-38. (PMID: 24978641)
Cancer Res. 2006 Jun 15;66(12):6080-6. (PMID: 16778180)
Nature. 2011 Mar 24;471(7339):513-7. (PMID: 21430779)
Int J Cancer. 2010 Dec 15;127(12):2893-917. (PMID: 21351269)
RNA Biol. 2013 Oct;10(10):1597-601. (PMID: 24019000)
Nature. 2009 Nov 19;462(7271):315-22. (PMID: 19829295)
Nat Med. 2011 Mar;17(3):330-9. (PMID: 21386836)
J Natl Cancer Inst. 2013 Mar 20;105(6):433-42. (PMID: 23365201)
Cancer Lett. 2014 Jan 28;342(2):170-7. (PMID: 22289720)
J Invest Dermatol. 2013 Feb;133(2):518-27. (PMID: 22931929)
J Invest Dermatol. 2013 Mar;133(3):768-75. (PMID: 23151846)
Cancer Res. 2008 Mar 1;68(5):1362-8. (PMID: 18316599)
J Biol Chem. 2011 May 13;286(19):16606-14. (PMID: 21454583)
J Cutan Pathol. 2009 Feb;36(2):197-205. (PMID: 18647205)
Cancer Lett. 2007 Aug 8;253(1):14-24. (PMID: 17188427)
Nature. 2011 Feb 10;470(7333):264-8. (PMID: 21307941)
Am J Dermatopathol. 2013 Jun;35(4):412-8. (PMID: 23051629)
Mol Cell. 2010 Jun 11;38(5):662-74. (PMID: 20541999)
Int J Cancer. 2010 Jun 1;126(11):2553-62. (PMID: 19830692)
Nature. 2008 Nov 6;456(7218):130-4. (PMID: 18820678)
Oncogene. 2013 Mar 28;32(13):1616-25. (PMID: 22614017)
J Mol Med (Berl). 2013 Jul;91(7):791-801. (PMID: 23529762)
PLoS One. 2013;8(2):e56824. (PMID: 23437250)
G Ital Dermatol Venereol. 2010 Feb;145(1):37-45. (PMID: 20197744)
Genome Biol. 2014;15(1):R6. (PMID: 24393600)
Pigment Cell Melanoma Res. 2011 Jun;24(3):525-37. (PMID: 21435193)
Pigment Cell Melanoma Res. 2011 Apr;24(2):352-60. (PMID: 21375697)
Mol Cell. 2012 Oct 26;48(2):219-30. (PMID: 22959273)
Cell. 2012 Sep 14;150(6):1135-46. (PMID: 22980977)
Physiol Genomics. 2013 Nov 15;45(22):1049-59. (PMID: 24046283)
Nucleic Acids Res. 2012 May;40(10):4334-46. (PMID: 22278882)
Br J Cancer. 2010 Sep 7;103(6):820-6. (PMID: 20736948)
Cell Death Dis. 2014;5:e1008. (PMID: 24457952)
Epigenetics. 2011 Mar;6(3):388-94. (PMID: 21081840)
J Transl Med. 2010;8:27. (PMID: 20302635)
Pigment Cell Melanoma Res. 2010 Jun;23(3):419-29. (PMID: 20374520)
Oncotarget. 2014 Oct 15;5(19):8959-69. (PMID: 25344859)
Nature. 2013 Jan 10;493(7431):231-5. (PMID: 23201690)
Mol Cancer Ther. 2004 Apr;3(4):425-35. (PMID: 15078986)
Cell Death Differ. 2010 May;17(5):801-10. (PMID: 19893569)
Nature. 2014 Mar 6;507(7490):109-13. (PMID: 24572365)
Inflammation. 2014 Oct;37(5):1744-50. (PMID: 24799320)
Adv Genet. 2010;70:27-56. (PMID: 20920744)
Cell. 2007 Jun 29;129(7):1311-23. (PMID: 17604720)
Nature. 2010 Apr 15;464(7291):1071-6. (PMID: 20393566)
Melanoma Res. 2005 Feb;15(1):15-20. (PMID: 15714116)
J Cell Physiol. 2011 Sep;226(9):2360-9. (PMID: 21660959)
BMC Cancer. 2010;10:63. (PMID: 20178651)
Oncogene. 2006 Nov 2;25(52):6975-85. (PMID: 16715135)
Front Biosci. 2008;13:2435-43. (PMID: 17981724)
Oncogene. 2000 Oct 19;19(44):5111-5. (PMID: 11042700)
Melanoma Res. 2012 Apr;22(2):101-13. (PMID: 22209751)
فهرسة مساهمة: Keywords: 5hmC, 5-hydroxymethylcytosine; 5mC, 5-methylcytosine; ACE, angiotensin converting enzyme; ANCR, anti-differentiation non-coding RNA; ANRIL, antisense noncoding RNA in INK4 locus; ASK1, apoptosis signal-regulating kinase 1; ATRA, all-trans retinoic acid; BANCR, BRAF-activated non-coding RNA; BCL-2, B-cell lymphoma 2; BRAF, B-Raf proto-oncogene, serine/threonine kinase; BRG1, ATP-dependent helicase SMARCA4; CAF-1, chromatin assembly factor-1; CBX7, chromobox homolog 7; CCND1, cyclin D1; CD28, cluster of differentiation 28; CDK, cyclin-dependent kinase; CDKN2A/B, cyclin-dependent kinase inhibitor 2A/B; CHD8, chromodomain-helicase DNA-binding protein 8; CREB, cAMP response element-binding protein; CUDR, cancer upregulated drug resistant; Cdc6, cell division cycle 6; DNA methylation/demethylation; DNMT, DNA methyltransferase; EMT, epithelial-mesenchymal transition; ERK, extracellular signal-regulated kinase; EZH2, enhancer of zeste homolog 2; GPCRs, G-protein coupled receptors; GSK3a, glycogen synthase kinase 3 α; GWAS, genome-wide association study; HDAC, histone deacetylase; HOTAIR, HOX antisense intergenic RNA; IAP, inhibitor of apoptosis; IDH2, isocitrate dehydrogenase; IFN, interferon, interleukin 23; JNK, Jun N-terminal kinase; Jak/STAT, Janus kinase/signal transducer and activator of transcription; MAFG, v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog G; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MAPK, mitogen-activated protein kinase; MC1R, melanocortin-1 receptor; MGMT, O6-methylguanine-DNA methyltransferase; MIF, macrophage migration inhibitory factor; MITF, microphthalmia-associated transcription factor; MRE, miRNA recognition element; MeCP2, methyl CpG binding protein 2; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NOD, nucleotide-binding and oligomerization domain; PBX, pre-B-cell leukemia homeobox; PEDF, pigment epithelium derived factor; PI3K, phosphatidylinositol-4, 5-bisphosphate 3-kinase; PIB5PA, phosphatidylinositol-4, 5-biphosphate 5-phosphatase A; PKA, protein kinase A; PRC, polycomb repressor complex; PSF, PTB associated splicing factor; PTB, polypyrimidine tract-binding; PTEN, phosphatase and tensin homolog; RARB, retinoic acid receptor-β2; RASSF1A, Ras association domain family 1A; SETDB1, SET Domain, bifurcated 1; SPRY4, Sprouty 4; STAU1, Staufen1; SWI/SNF, SWItch/Sucrose Non-Fermentable; TCR, T-cell receptor; TET, ten eleven translocase; TGF β, transforming growth factor β; TINCR, tissue differentiation-inducing non-protein coding RNA; TOR, target of rapamycin; TP53, tumor protein 53; TRAF6, TNF receptor-associated factor 6; UCA1, urothelial carcinoma-associated 1; ceRNA, competitive endogenous RNAs; chromatin modification; chromatin remodeling; epigenetics; gene regulation; lncRNA, long ncRNA; melanoma; miRNA, micro RNA; ncRNA, non-coding RNA; ncRNAs; p14ARF, p14 alternative reading frame; p16INK4a, p16 inhibitor of CDK4; pRB, retinoblastoma protein; snoRNA, small nucleolar RNA; α-MSHm, α-melanocyte stimulating hormone
المشرفين على المادة: 0 (Histones)
0 (MAS1 protein, human)
0 (Proto-Oncogene Mas)
0 (RNA, Long Noncoding)
تواريخ الأحداث: Date Created: 20150115 Date Completed: 20151005 Latest Revision: 20220321
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC4622872
DOI: 10.1080/15592294.2014.1003746
PMID: 25587943
قاعدة البيانات: MEDLINE
الوصف
تدمد:1559-2308
DOI:10.1080/15592294.2014.1003746